A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

NCT04722172 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Acalabrutinib
DRUG: Obinutuzumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]